Samir Gupta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9188511/publications.pdf

Version: 2024-02-01

135 papers	5,448 citations	41 h-index	95266 68 g-index
135	135	135	6733
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Reply. Gastroenterology, 2023, 164, 1029-1030.	1.3	O
2	Polygenic Risk Scores for Follow Up After Colonoscopy and Polypectomy: Another Tool for Risk Stratification and Planning Surveillance?. Clinical Gastroenterology and Hepatology, 2023, 21, 29-32.	4.4	3
3	Pancreas Cancer Incidence and Pancreas Cancer-Associated Mortality Are Low in National Cohort of 7211 Pancreas Cyst Patients. Digestive Diseases and Sciences, 2022, 67, 1065-1072.	2.3	7
4	Distinct Clinical Physiologic Phenotypes of Patients With Laryngeal Symptoms Referred for Reflux Evaluation. Clinical Gastroenterology and Hepatology, 2022, 20, 776-786.e1.	4.4	8
5	Upper Esophageal Sphincter Compression Device as an Adjunct to Proton Pump Inhibition for Laryngopharyngeal Reflux. Digestive Diseases and Sciences, 2022, 67, 3045-3054.	2.3	5
6	Increasing Colorectal Cancer Incidence Before and After Age 50: Implications for Screening Initiation and Promotion of "On-Time―Screening. Digestive Diseases and Sciences, 2022, 67, 4086-4091.	2.3	11
7	Review article: Lynch Syndrome—a mechanistic and clinical management update. Alimentary Pharmacology and Therapeutics, 2022, 55, 960-977.	3.7	8
8	Early-Onset Colorectal Cancer: A Call for Greater Rigor in Epidemiologic Studies. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 507-511.	2.5	1
9	Diagnosis and Management of Cancer Risk in the Gastrointestinal Hamartomatous Polyposis Syndromes: Recommendations From the US Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2022, 117, 846-864.	0.4	11
10	Diagnosis and management of cancer risk in the gastrointestinal hamartomatous polyposis syndromes: recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointestinal Endoscopy, 2022, 95, 1025-1047.	1.0	6
11	Screening for Colorectal Cancer. Hematology/Oncology Clinics of North America, 2022, 36, 393-414.	2.2	33
12	Diagnosis and Management of Cancer Risk in the Gastrointestinal Hamartomatous Polyposis Syndromes: Recommendations From the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 2022, 162, 2063-2085.	1.3	35
13	The COVID-19 Pandemic: Identifying Adaptive Solutions for Colorectal Cancer Screening in Underserved Communities. Journal of the National Cancer Institute, 2021, 113, 962-968.	6.3	43
14	Interventions to ensure follow-up of positive fecal immunochemical tests: An international survey of screening programs. Journal of Medical Screening, 2021, 28, 51-53.	2.3	16
15	Systematic Review of Prevalence, Risk Factors, and Risk for Metachronous Advanced Neoplasia in Patients With Young-Onset Colorectal Adenoma. Clinical Gastroenterology and Hepatology, 2021, 19, 680-689.e12.	4.4	20
16	Framework and Strategies to Eliminate Disparities in Colorectal Cancer Screening Outcomes. Annual Review of Medicine, 2021, 72, 383-398.	12.2	18
17	An Update on the Epidemiology, Molecular Characterization, Diagnosis, and Screening Strategies for Early-Onset Colorectal Cancer. Gastroenterology, 2021, 160, 1041-1049.	1.3	119
18	Realizing the Promise of Personalized Colorectal Cancer Screening in Practice. Journal of the National Cancer Institute, 2021 , 113 , 1120 - 1122 .	6.3	6

#	Article	IF	Citations
19	Response. Gastrointestinal Endoscopy, 2021, 93, 1198-1201.	1.0	0
20	Time to Colonoscopy After Abnormal Stool-Based Screening and Risk for Colorectal Cancer Incidence and Mortality. Gastroenterology, 2021, 160, 1997-2005.e3.	1.3	40
21	The effect of deadlines on cancer screening completion: a randomized controlled trial. Scientific Reports, 2021, 11, 13876.	3.3	9
22	A strategy for validation of variables derived from large-scale electronic health record data. Journal of Biomedical Informatics, 2021, 121, 103879.	4.3	11
23	Young-onset colorectal cancer risk among individuals with iron-deficiency anaemia and haematochezia. Gut, 2021, 70, 1529-1537.	12.1	18
24	IS PROMOTION OF FECAL IMMUNOCHEMICAL TESTING "FIT―TO ADDRESS COVID-19 DISRUPTIONS TO COLORECTAL CANCER SCREENING?. Gastroenterology, 2021, , .	1.3	0
25	A prospective randomized study comparing jumbo biopsy forceps to cold snare for the resection of diminutive colorectal polyps. Surgical Endoscopy and Other Interventional Techniques, 2020, 34, 1206-1213.	2.4	12
26	Lower Abnormal Fecal Immunochemical Test Cut-Off Values Improve Detection of Colorectal Cancer in System-Level Screens. Clinical Gastroenterology and Hepatology, 2020, 18, 647-653.	4.4	8
27	Peroral Endoscopic Myotomy versus Pneumatic Dilation in Achalasia: Dissecting the Randomized Controlled Trial. Gastroenterology, 2020, 158, 276-277.	1.3	5
28	Does Colon Polyp Surveillance Improve Patient Outcomes?. Gastroenterology, 2020, 158, 436-440.	1.3	14
29	Baseline Colonoscopy Findings Associated With 10-Year Outcomes in a Screening Cohort Undergoing Colonoscopy Surveillance. Gastroenterology, 2020, 158, 862-874.e8.	1.3	51
30	AGA Clinical Practice Guidelines on Management of Gastric Intestinal Metaplasia. Gastroenterology, 2020, 158, 693-702.	1.3	177
31	A Systematic Review of Repeat Fecal Occult Blood Tests for Colorectal Cancer Screening. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 278-287.	2.5	13
32	Racial and Ethnic Disparities in Colorectal Cancer Screening Pose Persistent Challenges to Health Equity. Clinical Gastroenterology and Hepatology, 2020, 18, 1691-1693.	4.4	15
33	Endoscopic Recognition and Management Strategies for Malignant Colorectal Polyps: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastrointestinal Endoscopy, 2020, 92, 997-1015.e1.	1.0	35
34	Screening and Surveillance Colonoscopy and COVID-19: Avoiding More Casualties. Gastroenterology, 2020, 159, 1205-1208.	1.3	26
35	Population-Based Analysis of Differences in Gastric Cancer Incidence Among Races and Ethnicities in Individuals Age 50 Years and Older. Gastroenterology, 2020, 159, 1705-1714.e2.	1.3	51
36	Cumulative Risk for Incident and Fatal Colorectal Cancer after Polypectomy. Gastroenterology, 2020, 159, 1992.	1.3	1

#	Article	IF	Citations
37	Endoscopic Recognition and Management Strategies for Malignant Colorectal Polyps: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 2020, 159, 1916-1934.e2.	1.3	68
38	Assessment of neonatal perfusion. Seminars in Fetal and Neonatal Medicine, 2020, 25, 101144.	2.3	9
39	Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2020, 115, 415-434.	0.4	103
40	Mailed fecal immunochemical test outreach for colorectal cancer screening: Summary of a Centers for Disease Control and Prevention–sponsored Summit. Ca-A Cancer Journal for Clinicians, 2020, 70, 283-298.	329.8	75
41	Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society TaskÂForce on Colorectal Cancer. Gastrointestinal Endoscopy, 2020, 91, 463-485.e5.	1.0	163
42	Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 2020, 158, 1131-1153.e5.	1.3	228
43	Spotlight: Gastric Intestinal Metaplasia. Gastroenterology, 2020, 158, 704.	1.3	8
44	Outreach and Inreach Strategies for Colorectal Cancer Screening Among Latinos at a Federally Qualified Health Center: A Randomized Controlled Trial, 2015–2018. American Journal of Public Health, 2020, 110, 587-594.	2.7	11
45	Risk Factors for Early-Onset Colorectal Cancer. Gastroenterology, 2020, 159, 492-501.e7.	1.3	121
46	Potential impact of family history–based screening guidelines on the detection of earlyâ€onset colorectal cancer. Cancer, 2020, 126, 3013-3020.	4.1	45
47	Reply. Gastroenterology, 2020, 159, 403-404.	1.3	0
48	Diagnostic colonoscopy completion after abnormal fecal immunochemical testing and quality of tests used at 8 Federally Qualified Health Centers in Southern California: Opportunities for improving screening outcomes. Cancer, 2019, 125, 4203-4209.	4.1	25
49	Screening initiation with FIT or colonoscopy: Post-hoc analysis of a pragmatic, randomized trial. Preventive Medicine, 2019, 118, 332-335.	3.4	9
50	Cost-Effectiveness and National Effects of Initiating Colorectal Cancer Screening for Average-Risk Persons at Age 45 Years Instead of 50 Years. Gastroenterology, 2019, 157, 137-148.	1.3	133
51	Patient-Reported Barriers to Completing a Diagnostic Colonoscopy Following Abnormal Fecal Immunochemical Test Among Uninsured Patients. Journal of General Internal Medicine, 2019, 34, 1730-1736.	2.6	27
52	Mailed Outreach Is Superior to Usual Care Alone for Colorectal Cancer Screening in the USA: A Systematic Review and Meta-analysis. Digestive Diseases and Sciences, 2019, 64, 2489-2496.	2.3	62
53	Risk factors for colorectal cancer significantly vary by anatomic site. BMJ Open Gastroenterology, 2019, 6, e000313.	2.7	44
54	Financial Incentives to Promote Colorectal Cancer Screening: A Longitudinal Randomized Control Trial. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1902-1908.	2.5	11

#	Article	IF	CITATIONS
55	Metformin Is Associated With Reduced Odds for Colorectal Cancer Among Persons With Diabetes. Clinical and Translational Gastroenterology, 2019, 10, e00092.	2.5	15
56	Ascertainment of Aspirin Exposure Using Structured and Unstructured Large-scale Electronic Health Record Data. Medical Care, 2019, 57, e60-e64.	2.4	16
57	Race/Ethnicity-, Socioeconomic Status-, and Anatomic Subsite-Specific Risks for Gastric Cancer. Gastroenterology, 2019, 156, 59-62.e4.	1.3	77
58	Collaborative orientation to advance value co-creation in buyer–seller relationships. Journal of Strategic Marketing, 2019, 27, 191-209.	5.5	13
59	see related Editorial on page 803: Family History of Colorectal Cancer in First-Degree Relatives and Metachronous Colorectal Adenoma. American Journal of Gastroenterology, 2018, 113, 899-905.	0.4	13
60	Overall Mortality and Pancreatic Cancer Mortality Among Patients With Pancreatic Cystic Neoplasms. Gastroenterology, 2018, 154, 1538-1539.	1.3	0
61	When Should Screening Stop for Elderly Individuals at Average and Increased Risk for Colorectal Cancer?. Clinical Gastroenterology and Hepatology, 2018, 16, 178-180.e1.	4.4	3
62	Adherence to colorectal cancer screening measured as the proportion of time covered. Gastrointestinal Endoscopy, 2018, 88, 323-331.e2.	1.0	17
63	Evaluating Two Evidence-Based Intervention Strategies to Promote CRC Screening Among Latino Adults in a Primary Care Setting. Journal of Racial and Ethnic Health Disparities, 2018, 5, 530-535.	3.2	11
64	Effect of CD4 Count on Treatment Toxicity and Tumor Recurrence in Human Immunodeficiency Virus–Positive Patients With Anal Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 100, 478-485.	0.8	14
65	Association of HIV Status With Outcomes of Anal Squamous Cell Carcinoma in the Era of Highly Active Antiretroviral Therapy. JAMA Oncology, 2018, 4, 120.	7.1	21
66	Stereotactic Body Radiation Therapy Versus Surgery for Early Lung Cancer Among USÂVeterans. Annals of Thoracic Surgery, 2018, 105, 425-431.	1.3	60
67	When Should Patients Undergo Genetic Testing for Hereditary Colon Cancer Syndromes?. Clinical Gastroenterology and Hepatology, 2018, 16, 181-183.	4.4	7
68	Structured Approach for Evaluating Strategies for Cancer Ascertainment Using Large-Scale Electronic Health Record Data. JCO Clinical Cancer Informatics, 2018, 2, 1-12.	2.1	21
69	Impact of a Clinical Decision Support System on Guideline Adherence of Surveillance Recommendations for Colonoscopy After Polypectomy. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1321-1328.	4.9	17
70	Overcoming equivocality on projects in the fuzzy front end: Bringing social networks back in. Technovation, 2018, 78, 40-55.	7.8	8
71	Education, training, and accreditation of Neonatologist Performed Echocardiography in Europe—framework for practice. Pediatric Research, 2018, 84, 13-17.	2.3	32
72	NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 939-949.	4.9	116

#	Article	IF	Citations
73	Potential Intended and Unintended Consequences of Recommending Initiation of Colorectal Cancer Screening at Age 45 Years. Gastroenterology, 2018, 155, 950-954.	1.3	49
74	A Framework for Leveraging "Big Data―to Advance Epidemiology and Improve Quality: Design of the VA Colonoscopy Collaborative. EGEMS (Washington, DC), 2018, 6, 4.	2.0	8
75	Risk stratification of individuals with low-risk colorectal adenomas using clinical characteristics: a pooled analysis. Gut, 2017, 66, 446-453.	12.1	28
76	Taxonomy for colorectal cancer screening promotion: Lessons from recent randomized controlled trials. Preventive Medicine, 2017, 101, 229-234.	3.4	4
77	Replacing the Guaiac Fecal Occult Blood Test With the Fecal Immunochemical Test Increases Proportion of Individuals Screened in a Large Healthcare Setting. Clinical Gastroenterology and Hepatology, 2017, 15, 1265-1270.e1.	4.4	31
78	Incidence, Risk Factors, and Outcomes of Colorectal Cancer in Patients With Ulcerative Colitis With Low-Grade Dysplasia: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2017, 15, 665-674.e5.	4.4	124
79	Colorectal Cancer is A Leading Cause of Cancer Incidence and Mortality among Adults Younger than 50â€Years in the Usa: A Seer-Based Analysis with Comparison to Other Young-Onset Cancers. Journal of Investigative Medicine, 2017, 65, 311-315.	1.6	185
80	Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion. JAMA - Journal of the American Medical Association, 2017, 318, 806.	7.4	98
81	Tu1010 Adenoma Mention Rate (AMR): Using Colonoscopy Pathology Results As a Surrogate Marker for Colonoscopy Quality in Large Healthcare Systems. Gastrointestinal Endoscopy, 2017, 85, AB538.	1.0	0
82	Tu1019 Adenoma Detection Rate (ADR) Irrespective of Indication Is Comparable to Screening ADR: Implications for Quality Monitoring. Gastrointestinal Endoscopy, 2017, 85, AB542.	1.0	1
83	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1465-1475.	4.9	109
84	Optimizing the Quality of the Colorectal Cancer Screening Continuum: A Call to Action. Journal of the National Cancer Institute, 2017 , 109 , .	6.3	3
85	Recommendations for neonatologist performed echocardiography in Europe: Consensus Statement endorsed by European Society for Paediatric Research (ESPR) and European Society for Neonatology (ESN). Pediatric Research, 2016, 80, 465-471.	2.3	113
86	Outreach invitations for FIT and colonoscopy improve colorectal cancer screening rates: A randomized controlled trial in a safetyâ€net health system. Cancer, 2016, 122, 456-463.	4.1	104
87	Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1010-1030.	4.9	179
88	Su1032 Mailed Outreach for Promoting Colorectal Cancer Screening: A Systematic Review and Meta-Analysis of Randomized Trials. Gastroenterology, 2016, 150, S450.	1.3	1
89	Cronkhite Canada Syndrome: Significant Response to Infliximab and a Possible Clue to Pathogenesis. American Journal of Gastroenterology, 2016, 111, 746-748.	0.4	22
90	Colorectal Cancer and Dysplasia in Inflammatory Bowel Disease: A Review of Disease Epidemiology, Pathophysiology, and Management. Cancer Prevention Research, 2016, 9, 887-894.	1.5	133

#	Article	IF	Citations
91	Fecal Immunochemical Testing: A Sensitive and Sustainable Approach for Population Colorectal CancerÂScreening?. Gastroenterology, 2016, 151, 554-555.	1.3	1
92	A prognostic model for advanced colorectal neoplasia recurrence. Cancer Causes and Control, 2016, 27, 1175-1185.	1.8	15
93	Financial Incentives for Promoting Colorectal Cancer Screening: A Randomized, Comparative Effectiveness Trial. American Journal of Gastroenterology, 2016, 111, 1630-1636.	0.4	61
94	Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis. BMJ, The, 2016, 355, i6188.	6.0	66
95	Tailored information increases patient/physician discussion of colon cancer risk and testing: The Cancer Risk Intake System trial. Preventive Medicine Reports, 2016, 4, 6-10.	1.8	10
96	Development of the Parkland-UT Southwestern Colonoscopy Reporting System (CoRS) for evidence-based colon cancer surveillance recommendations. Journal of the American Medical Informatics Association: JAMIA, 2016, 23, 402-406.	4.4	12
97	Expert consensus statement â€~Neonatologist-performed Echocardiography (NoPE)'—training and accreditation in UK. European Journal of Pediatrics, 2016, 175, 281-287.	2.7	77
98	Colorectal Cancer Screening, Version 1.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 959-968.	4.9	80
99	Post-polypectomy Guideline Adherence: Importance of Belief in Guidelines, Not Guideline Knowledge or Fear of Missed Cancer. Digestive Diseases and Sciences, 2015, 60, 2937-2945.	2.3	32
100	Impact of Risk Assessment and Tailored versus Nontailored Risk Information on Colorectal Cancer Testing in Primary Care: A Randomized Controlled Trial. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1523-1530.	2.5	17
101	Editorial: Trouble in Paris (Classification): Polyp Morphology Is in The Eye of The Beholder. American Journal of Gastroenterology, 2015, 110, 188-191.	0.4	8
102	Interdependency, dynamism, and variety (IDV) network modeling to explain knowledge diffusion at the fuzzy front-end of innovation. Journal of Business Research, 2015, 68, 2434-2442.	10.2	15
103	How Can We Boost Colorectal and Hepatocellular Cancer Screening Among Underserved Populations?. Current Gastroenterology Reports, 2015, 17, 22.	2.5	9
104	Molecular Markers of Carcinogenesis for Risk Stratification of Individuals with Colorectal Polyps: A Caseâ€"Control Study. Cancer Prevention Research, 2014, 7, 1023-1034.	1.5	4
105	Neighborhood effects in a behavioral randomized controlled trial. Health and Place, 2014, 30, 293-300.	3.3	8
106	Importance of Determining Indication for Colonoscopy: Implications for Practice and Policy. Clinical Gastroenterology and Hepatology, 2014, 12, 1958-1963.e3.	4.4	11
107	Physicians, Clinics, and Neighborhoods: Multiple Levels of Influence on Colorectal Cancer Screening. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1346-1355.	2.5	19
108	Colorectal cancer among firstâ€degree relatives of individuals with adenomas: The risk is elevated, but now what?. Cancer, 2014, 120, 4-6.	4.1	3

#	Article	IF	Citations
109	The Colorectal Cancer Screening Process in Community Settings: A Conceptual Model for the Population-Based Research Optimizing Screening through Personalized Regimens Consortium. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1147-1158.	2.5	64
110	Challenges and Possible Solutions to Colorectal Cancer Screening for the Underserved. Journal of the National Cancer Institute, 2014, 106, dju032-dju032.	6.3	182
111	Predictors of Guideline-Consistent Colon Cancer Surveillance Recommendations After Polypectomy. American Journal of Gastroenterology, 2014, 109, S611.	0.4	О
112	Abstract PC01-02: Colorectal cancer screening for African Americans: Should we be screening at an earlier age? Con., 2014,,.		0
113	Investigating the European perspective of neonatal point-of-care echocardiography in the neonatal intensive care unit—a pilot study. European Journal of Pediatrics, 2013, 172, 907-911.	2.7	24
114	Mo1097 Interventions to Increase Colorectal Cancer Screening Among Underserved Populations: A Systematic Review. Gastroenterology, 2013, 144, S-576.	1.3	1
115	Improving Hepatocellular Carcinoma Screening: Applying Lessons From Colorectal Cancer Screening. Clinical Gastroenterology and Hepatology, 2013, 11, 472-477.	4.4	49
116	Implementation of routine screening for Lynch syndrome in university and safety-net health system settings: successes and challenges. Genetics in Medicine, 2013, 15, 925-932.	2.4	22
117	Comparative Effectiveness of Fecal Immunochemical Test Outreach, Colonoscopy Outreach, and Usual Care for Boosting Colorectal Cancer Screening Among the Underserved. JAMA Internal Medicine, 2013, 173, 1725-32.	5.1	184
118	Measurement of Colorectal Cancer Test Use With Medical Claims Data in a Safety-Net Health System. American Journal of the Medical Sciences, 2013, 345, 99-103.	1.1	10
119	Failure Rates in the Hepatocellular Carcinoma Surveillance Process. Cancer Prevention Research, 2012, 5, 1124-1130.	1.5	175
120	Strategies for Reducing Colorectal Cancer Among Blacks. Archives of Internal Medicine, 2012, 172, 182.	3.8	11
121	Polyps With Advanced Neoplasia Are Smaller in the Right Than in the Left Colon: Implications for Colorectal Cancer Screening. Clinical Gastroenterology and Hepatology, 2012, 10, 1395-1401.e2.	4.4	68
122	Inactivity and the dynamics of relationship development: a proposed model. Journal of Strategic Marketing, 2010, 18, 257-273.	5.5	34
123	Risk of pancreatic cancer by alcohol dose, duration, and pattern of consumption, including binge drinking: a population-based study. Cancer Causes and Control, 2010, 21, 1047-1059.	1.8	74
124	Microsatellite instability among individuals of Hispanic origin with colorectal cancer. Cancer, 2010, 116, 4965-4972.	4.1	30
125	Will Test-Specific Adherence Predict the Best Colorectal Cancer Screening Strategy?. Annals of Internal Medicine, 2009, 150, 359.	3.9	4
126	Pancreatitis and pancreatic cancer in two large pooled case–control studies. Cancer Causes and Control, 2009, 20, 1723-1731.	1.8	58

#	Article	IF	CITATIONS
127	Diffusing knowledge-based core competencies for leveraging innovation strategies: Modelling outsourcing to knowledge process organizations (KPOs) in pharmaceutical networks. Industrial Marketing Management, 2009, 38, 219-227.	6.7	64
128	Variation of Agreement in Polyp Size Measurement Between Computed Tomographic Colonography and Pathology Assessment: Clinical Implications. Clinical Gastroenterology and Hepatology, 2008, 6, 220-227.	4.4	21
129	Colorectal Polyps: The Scope and Management of the Problem. American Journal of the Medical Sciences, 2008, 336, 407-417.	1.1	15
130	New-Onset Diabetes and Pancreatic Cancer. Clinical Gastroenterology and Hepatology, 2006, 4, 1366-1372.	4.4	104
131	Diabetes Mellitus and Pancreatic Cancer in a Population-Based Case-Control Study in the San Francisco Bay Area, California. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1458-1463.	2.5	99
132	Advancing Theory of New B-to-B Relationships: Examining Network Participants' Interpretations of E-Intermediary Innovation, Diffusion, and Adoption Processes. Journal of Business-to-Business Marketing, 2006, 13, 1-27.	1.5	49
133	Management of Nonsteroidal, Anti-inflammatory, Drug-Associated Dyspepsia. Gastroenterology, 2005, 129, 1711-1719.	1.3	7
134	Diffusion process models and strategic performance theory for new B2B electronic ventures. Journal of Business and Industrial Marketing, 2004, 19, 23-38.	3.0	11
135	Glucose-6-Phosphate Dehydrogenase Deficiency and Neonatal Jaundice in Al-Hofuf Area. Annals of Saudi Medicine, 1999, 19, 156-158.	1.1	9